Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorJun Zhang, MD, PhD
About this trial
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
Eligibility criteria
Qualifiers
Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Life expectancy ≥12 weeks
Males and females age ≥ 18 years
Disqualifiers
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or if the participant is in the follow-up period of an interventional study
Participation in another clinical study with an investigational product during the last 4 weeks prior to enrollment on this study
Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
Mixed small cell and non-small cell lung cancer histology
Trial design
Treatments tested in this trial
- Not listed
Trial groups
44 Participants
are grouped into 1 trial groupSponsors and collaborators
Jun Zhang, MD, PhD
Lead sponsor
University of Kansas Medical Center
Sponsor institution
Rhode Island Hospital
Collaborator
Source ClinicalTrials.gov